- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Logrank Test.
Displaying page 1 of 1.
EudraCT Number: 2012-002852-17 | Sponsor Protocol Number: GOG-0277 | Start Date*: 2013-03-13 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcoma | |||||||||||||
Medical condition: Patients with high risk uterine LMS, FIGO stage I (confined to corpus +/- cervix). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001885-17 | Sponsor Protocol Number: CTSUTHRIVE1 | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524. | |||||||||||||
Medical condition: Cardiovascular disease: History of myocardial infarction; or cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation);... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DK (Completed) SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002944-10 | Sponsor Protocol Number: c16174 | Start Date*: 2019-02-27 |
Sponsor Name:Memorial Sloan Kettering Cancer Center | ||
Full Title: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Medical condition: Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002570-30 | Sponsor Protocol Number: EFC5505 | Start Date*: 2005-12-07 | |||||||||||
Sponsor Name:Sanofi-Synthelabo Recherche | |||||||||||||
Full Title: A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metas... | |||||||||||||
Medical condition: Patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV; at risk of cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) ES (Completed) PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006550-96 | Sponsor Protocol Number: TN-07 | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:NIDDK TYPE 1 DIABETES TRIALNET | |||||||||||||
Full Title: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus | |||||||||||||
Medical condition: prevention of type 1 diabetes mellitus in subjects at risk for T1DM | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FI (Completed) DE (Completed) GB (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000992-26 | Sponsor Protocol Number: VAPOR002 | Start Date*: 2016-06-29 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Volatile Anesthetic Protection Of Renal transplants 2 | ||
Medical condition: kidney transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DK (Completed) ES (Ongoing) NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002940-17 | Sponsor Protocol Number: N16NCI | Start Date*: 2016-11-25 | |||||||||||
Sponsor Name:Antoni van Leeuwenhoek | |||||||||||||
Full Title: Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer | |||||||||||||
Medical condition: stage 2-3 adenocarcinoma of the colon | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002877-27 | Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 | Start Date*: 2023-07-06 | ||||||||||||||||
Sponsor Name:Cancer Trials Ireland | ||||||||||||||||||
Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P... | ||||||||||||||||||
Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003337-41 | Sponsor Protocol Number: CS1003-305 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:CStone Pharmaceuticals (Suzhou) Co., Ltd. | |||||||||||||
Full Title: A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First... | |||||||||||||
Medical condition: unresectable advanced hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) PL (Ongoing) ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001319-36 | Sponsor Protocol Number: FIERCE-21(B-701-U21) | Start Date*: 2017-08-23 | |||||||||||
Sponsor Name:BioClin Therapeutics, Inc. | |||||||||||||
Full Title: A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After,... | |||||||||||||
Medical condition: Treatment of progressed or refractory metastatic UCC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005535-24 | Sponsor Protocol Number: ABROGATE-5527 | Start Date*: 2016-06-07 | |||||||||||||||||||||
Sponsor Name:Univeristy of South Florida | |||||||||||||||||||||||
Full Title: Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's) | |||||||||||||||||||||||
Medical condition: Granulomatosis with polyangiitis (GPA; Wegener's granulomatosis) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012807-25 | Sponsor Protocol Number: IIL-MCL0208 | Start Date*: 2010-01-28 | ||||||||||||||||||||||||||
Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS | ||||||||||||||||||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A... | ||||||||||||||||||||||||||||
Medical condition: Mantel cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) PT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005276-16 | Sponsor Protocol Number: ET743-OVA-301 | Start Date*: 2005-10-27 | |||||||||||
Sponsor Name:Pharma Mar S.A. | |||||||||||||
Full Title: An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. | |||||||||||||
Medical condition: Advanced relapsed ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000199-12 | Sponsor Protocol Number: A011-13 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) SE (Ongoing) DE (Ongoing) DK (Ongoing) ES (Ongoing) AT (Ongoing) NL (Ongoing) IT (Ongoing) CZ (Ongoing) PL (Ongoing) PT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.